276 results on '"Perry, Chava"'
Search Results
2. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis
3. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies
4. Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion
5. Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy
6. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
7. The Clinical Significance of Circulating Lymphocytes Morphology in Diffuse Large B-Cell Lymphoma As Determined by a Novel, Highly Sensitive Microscopy
8. Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects
9. Primary Cardiac Lymphoma Patients Presenting With Heart Failure
10. Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series
11. Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients
12. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study
13. Image-Based Deep Learning Detection of High-Grade B-Cell Lymphomas Directly from Hematoxylin and Eosin Images
14. PB2288: INCIDENCE OF NEWLY DIAGNOSED AGGRESSIVE NON-HODGKIN’S LYMPHOMA BEFORE AND DURING THE COVID-19 PANDEMIC IN ISRAEL - A SINGLE CENTER RETROSPECTIVE STUDY
15. Hodgkin lymphoma of the gastrointestinal tract in patients with inflammatory bowel disease: Portrait of a rare clinical entity
16. Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects
17. Interim PET-CT–guided therapy in elderly patients with Hodgkin lymphoma—a retrospective national multi-center study
18. Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study
19. Toxicity and efficacy of autologous hematopoietic cell transplantation in elderly patients with aggressive lymphoma: a historical prospective study
20. The Generation of Chromosomal Alterations During Mitosis in Primary Central Nervous System Diffuse Large B-cell Lymphoma
21. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to anti CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
22. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “ Real‐World ” study
23. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
24. The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study
25. Lymphoproliferative disease detected by breast cancer screening
26. COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge
27. The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients
28. The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study.
29. REGEN‐COV antibody combination in patients with lymphoproliferative malignancies and SARS‐CoV‐2 infection
30. Be on guard: longer monitoring for very–late onset hepatitis B virus reactivation after chemo-immunotherapy?
31. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia
32. Is There a Role for [18F]FDG PET-CT in Staging MALT Lymphoma?
33. BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses
34. A Comprehensive Toxicity and Efficacy Analysis of Different Bridging Therapies Prior to Anti CD19-CAR-T Cell Therapy in Patients with DLBCL- a National Multi-Center Cohort Study
35. COVID-19 in patients with CLL: how can we change the odds?
36. Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells
37. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies
38. Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching
39. Characteristics of primary splenic diffuse large B-cell lymphoma and role of splenectomy in improving survival
40. Feasibly of CD24/CD11b as a Screening Test for Hematological Malignancies
41. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study
42. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma
43. Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells
44. Circulating Wnt Ligands Activate the Wnt Signaling Pathway in Mature Erythrocytes
45. Lower Patient Anxiety and Unchanged Levels of Adherence to Hemato-Oncologic Treatment in Response to New Measures to Reduce Hospital Exposure Risk to COVID-19
46. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
47. Correlation Between BNT162b2 mRNA Covid-19 Vaccine-associated Hypermetabolic Lymphadenopathy and Humoral Immunity in Patients With Hematologic Malignancy
48. Toxicity and Efficacy of CAR-T in Patients with DLBCL Above the Age of 70 Years Compare to Younger Patients – a Matched Control Multi-Center Cohort Study
49. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies.
50. Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.